Sodium Phenylbutyrate for PFIC: Mechanism, Approval, and Clinical Impact
Sodium phenylbutyrate secured regulatory approval in Japan in August 2026 for progressive familial intrahepatic cholestasis types 1 and 2, marking a major shift in targeting underlying disease mechanisms rather than ... Read More